Author:
Jiménez-López Estela,Sánchez-Morla Eva María,López-Villarreal Ana,Aparicio Ana Isabel,Martínez-Vizcaíno Vicente,Vieta Eduard,Rodriguez-Jimenez Roberto,Santos José Luis
Abstract
AbstractBackground:Bipolar disorder (BD) and schizophrenia (SZ) are characterized by neurocognitive and functional deficits with marked heterogeneity. It has been suggested that BD with a history of psychotic symptoms (BD-P) could constitute a phenotypically homogeneous subtype characterized by greater neurocognitive and functional impairments, or by a distinct trajectory of such deficits. The aim of this study was to compare the neurocognitive and functional course of euthymic BD-P, euthymic BD patients without a history of psychosis (BD-NP), stabilized patients with schizophrenia and healthy subjects, during a five-year follow-up.Methods:Neurocognitive and psychosocial function was examined in 100 euthymic patients with BD (50 BD-P, 50 BD-NP), 50 stabilized patients with schizophrenia (SZ), and 51 healthy controls (HC) at baseline (T1), and after a 5-year follow-up (T2).Results:The course of both neurocognitive performance and functional outcome of patients with SZ and BD (BD-P and BD-NP) is stable. The profile of neurocognitive impairment of patients with SZ or BD (BD-P and BD-NP), is similar, with only quantitative differences circumscribed to certain domains, such as working memory. The subgroup of patients with BD-NP does not show functional deterioration.Conclusions:We have not found evidence of progression in the neurocognitive or psychosocial impairment in any of the three groups of patients, although it cannot be dismissed the possibility of a subset of patients with a progressive course. Other longitudinal studies with larger samples and longer duration are necessary to confirm these findings.
Funder
Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS)
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
Madrid Regional Government
JanssenCilag
Lundbeck
Otsuka
Pfizer
Ferrer
Juste
Takeda
AB-Biotics
Allergan
Angelini
AstraZeneca
Bristol-Myers Squibb
Dainippon Sumitomo Pharma
Farmindustria
Forest Research Institute
Gedeon Richter
Glaxo-Smith-Kline
Janssen
Roche
Sanofi-Aventis
Servier
Shire
Sunovion
Brain and Behaviour Foundation
Spanish Ministry of Science and Innovation (CIBERSAM)
Seventh European Framework Programme (ENBREC)
Stanley Medical Research Institute
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献